Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (45) 45
humans (44) 44
oncology (44) 44
female (38) 38
aged (35) 35
middle aged (32) 32
chemotherapy (31) 31
breast cancer (29) 29
adult (26) 26
treatment outcome (22) 22
aged, 80 and over (19) 19
breast neoplasms - drug therapy (19) 19
survival (19) 19
cancer (18) 18
breast neoplasms - pathology (16) 16
male (16) 16
care and treatment (14) 14
metastasis (14) 14
therapy (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
analysis (12) 12
disease-free survival (12) 12
patients (12) 12
retrospective studies (12) 12
trastuzumab (11) 11
hematology, oncology and palliative medicine (10) 10
metastatic breast cancer (10) 10
cancer patients (9) 9
cancer therapies (9) 9
combination (9) 9
neoplasm metastasis (9) 9
breast neoplasms - mortality (8) 8
cell biology (8) 8
docetaxel (8) 8
efficacy (8) 8
kaplan-meier estimate (8) 8
postmenopausal women (8) 8
prognosis (8) 8
safety (8) 8
survival analysis (8) 8
tumors (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer research (7) 7
clinical trials (7) 7
medicine & public health (7) 7
metastases (7) 7
multivariate analysis (7) 7
neoplasm staging (7) 7
paclitaxel (7) 7
research (7) 7
studies (7) 7
trial (7) 7
anastrozole (6) 6
antineoplastic agents - therapeutic use (6) 6
chemotherapy, adjuvant (6) 6
epidermal growth factor (6) 6
erbb-2 protein (6) 6
her2 (6) 6
lung neoplasms - drug therapy (6) 6
multicenter (6) 6
open-label (6) 6
patient outcomes (6) 6
receptor, erbb-2 - metabolism (6) 6
surgery (6) 6
antineoplastic agents - adverse effects (5) 5
bevacizumab (5) 5
breast neoplasms - chemistry (5) 5
breast neoplasms - metabolism (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
disease progression (5) 5
double-blind (5) 5
endocrine therapy (5) 5
gene expression (5) 5
genes (5) 5
hematology (5) 5
mutation (5) 5
pathological complete response (5) 5
pertuzumab (5) 5
pharmacology & pharmacy (5) 5
physiology (5) 5
proportional hazards models (5) 5
research paper (5) 5
risk factors (5) 5
taxane (5) 5
time factors (5) 5
women (5) 5
anthracyclines (4) 4
antineoplastic agents - administration & dosage (4) 4
body mass index (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
cisplatin (4) 4
clinical medicine (4) 4
cohort studies (4) 4
erlotinib hydrochloride (4) 4
expression (4) 4
follow-up studies (4) 4
fulvestrant (4) 4
gemcitabine (4) 4
internal medicine (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Are All Patients Truly Hormone Receptor Negative?
by Moscetti, L
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2017, Volume 35, Issue 14, pp. 1627 - 1627
BREAST-CANCER | ONCOLOGY | ADJUVANT ENDOCRINE THERAPY | Cyclophosphamide | Receptors, Estrogen | Breast Neoplasms | Methotrexate | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
by Garassino, Marina Chiara, MD and Martelli, Olga, MD and Broggini, Massimo, PhD and Farina, Gabriella, MD and Veronese, Silvio, PhD and Rulli, Eliana, PhD and Bianchi, Filippo, MD and Bettini, Anna, MD and Longo, Flavia, MD and Moscetti, Luca, MD and Tomirotti, Maurizio, MD and Marabese, Mirko, PhD and Ganzinelli, Monica, PhD and Lauricella, Calogero, PhD and Labianca, Roberto, MD and Floriani, Irene, PhD and Giaccone, Giuseppe, MD and Torri, Valter, MD and Scanni, Alberto, MD and Marsoni, Silvia, MD and TAILOR Trialists and TAILOR trialists
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 981 - 988
Summary Background Erlotinib is registered for treatment of all patients with advanced non-small-cell lung cancer (NSCLC). However, its efficacy for treatment... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | SURVIVAL | GEFITINIB | MULTICENTER | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | CLINICAL-TRIALS | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | PROGRESSION-FREE | OPEN-LABEL | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Proto-Oncogene Proteins - genetics | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Taxoids - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged, 80 and over | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Care and treatment | Chemotherapy | Erlotinib | Clinical trials | Lung cancer, Non-small cell | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
by Daniele, Santini and Sandro, Barni and Salvatore, Intagliata and Alfredo, Falcone and Francesco, Ferraù and Domenico, Galetta and Luca, Moscetti and Nicla, La Verde and Toni, Ibrahim and Fausto, Petrelli and Enrico, Vasile and Laura, Ginocchi and Davide, Ottaviani and Flavia, Longo and Cinzia, Ortega and Antonio, Russo and Giuseppe, Badalamenti and Elena, Collovà and Gaetano, Lanzetta and Giovanni, Mansueto and Vincenzo, Adamo and Filippo, De Marinis and Antonietta, Satolli Maria and Flavia, Cantile and Andrea, Mancuso and Tanca, Francesca Maria and Raffaele, Addeo and Marco, Russano and Sterpi, M and Francesco, Pantano and Bruno, Vincenzi and Giuseppe, Tonini
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 18670
We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer. Data on... 
SIMULATED WEIGHTLESSNESS | CANCELLOUS BONE | MULTIDISCIPLINARY SCIENCES | ESTROGEN | ADULT-RATS | GROWING-RATS | SPACE-FLIGHT | SPACEFLIGHT | OVARIECTOMIZED RATS | BED REST | MESSENGER-RNA LEVELS | Carcinoma, Non-Small-Cell Lung - pathology | Young Adult | Humans | Middle Aged | Aged, 80 and over | Bone Neoplasms - secondary | Adult | Female | Lung Neoplasms - pathology | Male | Aged | Disease Progression | Adenocarcinoma | Bone cancer | Small cell lung carcinoma | Medical prognosis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Survival | Mentoring programs | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Brain metastases from solid tumors: Disease outcome according to type of treatment and therapeutic resources of the treating center
by Fabi, Alessandra and Felici, Alessandra and Metro, Giulio and Mirri, Alessandra and Bria, Emilio and Telera, Stefano and Moscetti, Luca and Russillo, Michelangelo and Lanzetta, Gaetano and Mansueto, Giovanni and Pace, Andrea and Maschio, Marta and Vidiri, Antonello and Sperduti, Isabella and Cognetti, Francesco and Carapella, Carmine M
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 2011, Volume 30, Issue 1, pp. 10 - 10
Background: To evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease... 
CELL LUNG-CANCER | BREAST-CANCER | TRIAL | MANAGEMENT | PROGNOSTIC-FACTORS | ONCOLOGY | RADIOSURGERY | CHEMOTHERAPY | RADIATION-THERAPY | Multivariate Analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Young Adult | Brain Neoplasms - secondary | Oncology Service, Hospital | Brain Neoplasms - therapy | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Health Care Surveys | Care and treatment | Chemotherapy | Brain tumors | Breast cancer | Diagnosis | Metastasis | Methods | Cancer | Confidence intervals | Brain | Medical imaging | Hospitals | Medical treatment | Radiation therapy | Neurosurgery | Clinical medicine | Multivariate analysis | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Two novel RHD alleles encoding truncated, nonfunctional D polypeptides
by Matteocci, Antonella and Mancuso, Tommaso and Pirelli, Federica and Hailemariam, Tiruneh and Moscetti, Alessandra and Castagna, Katiuscia and Collaretti, Angela and Rogai, Letizia and Nespoli, Guido and Grammatico, Paola and Pierelli, Luca
Transfusion, ISSN 0041-1132, 08/2018, Volume 58, Issue 8, pp. 2082 - 2083
HEMATOLOGY | BLOOD-DONORS | Biopolymers | Polypeptides
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status
by Omarini, Claudia and Bettelli, Stefania and Caprera, Cecilia and Manfredini, Samantha and Barbolini, Monica and Moscetti, Luca and Isca, Chrystel and Toss, Angela and Barbieri, Elena and Cortesi, Laura and Kaleci, Shaniko and Maiorana, Antonino and Tazzioli, Giovanni and Cascinu, Stefano and Piacentini, Federico
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 04/2019, Volume 145, Issue 4, pp. 821 - 828
PurposeHormone receptors (HR) status in HER2+breast cancer (BC) is a recognized stratification factor with relevant clinical implication. According to HR... 
Molecular pathways | HER2 positive | PI3K | MAPK | Trastuzumab | MULTICENTER | EVEROLIMUS | OPEN-LABEL | PHASE-3 | COMBINATION | PERTUZUMAB | CROSS-TALK | LAPATINIB | ONCOLOGY | DOUBLE-BLIND | Genetic research | Anopheles | Breast cancer | Hormones | Analysis | Genes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
by Grossi, Francesco and Grossi, Francesco and de Marinis, Filippo and de Marinis, Filippo and Gebbia, Vittorio and Gebbia, Vittorio and Riccardi, Ferdinando and Riccardi, Ferdinando and Caffo, Orazio and Caffo, Orazio and Gamucci, Teresa and Gamucci, Teresa and Ferraù, Francesco and Ferraù, Francesco and Nardi, Mario and Nardi, Mario and Moscetti, Luca and Moscetti, Luca and Boni, Luca and Boni, Luca and Dondi, Davide and Dondi, Davide and Galligioni, Enzo and Galligioni, Enzo
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2012, Volume 69, Issue 2, pp. 369 - 375
The aim of this study was to determine the activity and toxicity of two sequential chemotherapy regimens in the first-line treatment of advanced non-small-cell... 
First-line chemotherapy | Medicine & Public Health | Gemcitabine | Docetaxel | Non-small-cell lung cancer | Cancer Research | Oncology | Pharmacology/Toxicology | Cisplatin | Sequential chemotherapy | 1ST-LINE TREATMENT | PLUS CISPLATIN | CARBOPLATIN | MULTICENTER | METAANALYSIS | VINORELBINE | PACLITAXEL | ONCOLOGY | CLINICAL-TRIALS | COMBINATION CHEMOTHERAPY | PHARMACOLOGY & PHARMACY | DURATION | Lung Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Fatigue - chemically induced | Cisplatin - administration & dosage | Leukopenia - chemically induced | Adult | Deoxycytidine - adverse effects | Female | Neutropenia - chemically induced | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Oncology, Experimental | Clinical trials | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Complications and side effects | Cancer patients | Chemotherapy | Product development | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
by Venturelli, Marta and Guaitoli, Giorgia and Omarini, Claudia and Moscetti, Luca
Breast Cancer: Targets and Therapy, ISSN 1179-1314, 03/2018, Volume 10, pp. 39 - 49
Endocrine treatment represents the cornerstone of endocrine-sensitive premenopausal early breast cancer. The estrogen blockade plays a leading role in the... 
Amenorrhea | LHRH | Adjuvant | Hormone therapy | Women | Medical research | Care and treatment | Pituitary hormones | Menopause | Estrogen | Breast cancer | Glycoproteins | Tamoxifen | Radiotherapy | Chemotherapy | Medicine, Experimental | Luteinizing hormone | Health aspects | Cancer | Oncology | Patients | Cancer therapies | Studies | Signal transduction | Womens health | Fertility | Pituitary gland | Clinical medicine | Prostate | hormone therapy | amenorrhea | adjuvant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The xylanase inhibitor TAXI-III counteracts the necrotic activity of a Fusarium graminearum xylanase invitro and in durum wheat transgenic plants
by Moscetti, Ilaria and Faoro, Franco and Moro, Stefano and Sabbadin, Davide and Sella, Luca and Favaron, Francesco and D'Ovidio, Renato
Molecular Plant Pathology, ISSN 1464-6722, 08/2015, Volume 16, Issue 6, p. 583
  Summary The xylanase inhibitor TAXI-III has been proven to delay Fusarium head blight (FHB) symptoms caused by Fusarium graminearum in transgenic durum wheat... 
Genetically modified plants | Genetic engineering | Hydrogen peroxide | Wheat | Analysis | Crop diseases | Transgenic plants | Genes | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Neoadjuvant chemotherapy in triple‐negative breast cancer: A multicentric retrospective observational study in real‐life setting
by Gamucci, Teresa and Pizzuti, Laura and Sperduti, Isabella and Mentuccia, Lucia and Vaccaro, Angela and Moscetti, Luca and Marchetti, Paolo and Carbognin, Luisa and Michelotti, Andrea and Iezzi, Laura and Cassano, Alessandra and Grassadonia, Antonino and Astone, Antonio and Botticelli, Andrea and Magnolfi, Emanuela and Di Lauro, Luigi and Sergi, Domenico and Fuso, Paola and Tinari, Nicola and Barba, Maddalena and Maugeri‐Saccà, Marcello and Landucci, Elisabetta and Conti, Francesca and Sanguineti, Giuseppe and De Tursi, Michele and Iafrate, Gianni and Giordano, Antonio and Ciliberto, Gennaro and Natoli, Clara and Vici, Patrizia
Journal of Cellular Physiology, ISSN 0021-9541, 03/2018, Volume 233, Issue 3, pp. 2313 - 2323
We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple‐negative breast cancer (TNBC) patients treated in real‐world... 
rKi‐67 | neoadjuvant chemotherapy | pathological complete response | triple‐negative breast cancer | long‐term outcomes | triple-negative breast cancer | long-term outcomes | rKi-67 | MOLECULAR SUBTYPES | SURVIVAL | CARBOPLATIN | PHYSIOLOGY | BEVACIZUMAB | CYCLOPHOSPHAMIDE | DOCETAXEL | PACLITAXEL | CELL BIOLOGY | RATES | DOSE-DENSE DOXORUBICIN | Anthracyclines | Analysis | Oncology, Experimental | Adjuvant treatment | Breast cancer | Rankings | Research | Cancer | Statistical analysis | Taxane | Multivariate analysis | Patients | Survival | Chemotherapy | Anthracycline | Biopsy | Surgery | Predictions | Taxanes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
by Vici, Patrizia and Pizzuti, Laura and Natoli, Clara and Moscetti, Luca and Mentuccia, Lucia and Vaccaro, Angela and Sergi, Domenico and Di Lauro, Luigi and Trenta, Patrizia and Seminara, Patrizia and Santini, Daniele and Iezzi, Laura and Tinari, Nicola and Bertolini, Ilaria and Sini, Valentina and Mottolese, Marcella and Giannarelli, Diana and Giotta, Francesco and Maugeri-Saccà, Marcello and Barba, Maddalena and Marchetti, Paolo and Michelotti, Andrea and Sperduti, Isabella and Gamucci, Teresa
Breast Cancer Research and Treatment, ISSN 0167-6806, 10/2014, Volume 147, Issue 3, pp. 599 - 607
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth... 
Adjuvant chemotherapy | Medicine & Public Health | HER2-positive | Oncology | Breast cancer | Trastuzumab | Triple positive tumors | SURVIVAL | METAANALYSIS | RANDOMIZED-TRIALS | METASTASES | RECURRENCE RISK | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | RELAPSE | ONCOLOGY | HER2 | PLUS | Early Detection of Cancer | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Retrospective Studies | Chemotherapy, Adjuvant | Antimitotic agents | Care and treatment | Cancer patients | Patient outcomes | Analysis | Adjuvant treatment | Hormones, Sex | Antineoplastic agents | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
by Gamucci, Teresa and Mentuccia, Lucia and Natoli, Clara and Sperduti, Isabella and Cassano, Alessandra and Michelotti, Andrea and Di Lauro, Luigi and Sergi, Domenico and Fabi, Alessandra and Sarobba, Maria G and Marchetti, Paolo and Barba, Maddalena and Magnolfi, Emanuela and Maugeri‐Saccà, Marcello and Rossi, Ernesto and Sini, Valentina and Grassadonia, Antonino and Pellegrini, Domenica and Astone, Antonino and Nisticò, Cecilia and Angelini, Franco and Vaccaro, Angela and Pellegrino, Arianna and De Angelis, Claudia and Palleschi, Michela and Moscetti, Luca and Bertolini, Ilaria and Buglioni, Simonetta and Giordano, Antonio and Pizzuti, Laura and Vici, Patrizia
Journal of Cellular Physiology, ISSN 0021-9541, 06/2017, Volume 232, Issue 6, pp. 1571 - 1578
Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite... 
PHASE-III TRIAL | PHYSIOLOGY | EFFICACY | SAFETY | LETROZOLE | OPEN-LABEL | LOCALLY RECURRENT | COMBINATION | PLUS BEVACIZUMAB | CHEMOTHERAPY | PROGRESSION | CELL BIOLOGY | Multivariate Analysis | Bevacizumab - therapeutic use | Humans | Middle Aged | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Maintenance Chemotherapy | Retrospective Studies | Breast cancer | Metastasis | Angiogenesis inhibitors | Analysis | Paclitaxel | Therapy | Toxicity | Maintenance | Multivariate analysis | Patients | Survival | ErbB-2 protein | Bevacizumab | Metastases | Training | Breast | Taxanes | Cancer | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials
by Omarini, Claudia and Piacentini, Federico and Sperduti, Isabella and Barbolini, Monica and Isca, Chrystel and Nasso, Cecilia and Toss, Angela and D'Onofrio, Raffaella and Cortesi, Laura and Barbieri, Elena and Cascinu, Stefano and Moscetti, Luca
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 1046 - 1046
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
by Pizzuti, Laura and Giordano, Antonio and Michelotti, Andrea and Mazzotta, Marco and Natoli, Clara and Gamucci, Teresa and Angelis, Claudia and Landucci, Elisabetta and Diodati, Lucrezia and Iezzi, Laura and Mentuccia, Lucia and Fabbri, Agnese and Barba, Maddalena and Sanguineti, Giuseppe and Marchetti, Paolo and Tomao, Silverio and Mariani, Luciano and Paris, Ida and Lorusso, Vito and Vallarelli, Simona and Cassano, Alessandra and Aroldi, Francesca and Orlandi, Armando and Moscetti, Luca and Sergi, Domenico and Sarobba, Maria Giuseppina and Tonini, Giuseppe and Santini, Daniele and Sini, Valentina and Veltri, Enzo and Vaccaro, Angela and Ferrari, Laura and Tursi, Michele and Tinari, Nicola and Grassadonia, Antonino and Greco, Filippo and Botticelli, Andrea and Verde, Nicla and Zamagni, Claudio and Rubino, Daniela and Cortesi, Enrico and Magri, Valentina and Pomati, Giulia and Scagnoli, Simone and Capomolla, Elisabetta and Kayal, Ramy and Scinto, Angelo Fedele and Corsi, Domenico and Cazzaniga, Marina and Laudadio, Lucio and Forciniti, Samantha and Mancini, Maria and Carbognin, Luisa and Seminara, Patrizia and Barni, Sandro and Samaritani, Riccardo and Roselli, Mario and Portarena, Ilaria and Russo, Antonio and Ficorella, Corrado and Cannita, Katia and Carpano, Silvia and Pistelli, Mirco and Berardi, Rossana and Maria, Ruggero and Sperduti, Isabella and Ciliberto, Gennaro and Vici, Patrizia
Journal of Cellular Physiology, ISSN 0021-9541, 06/2019, Volume 234, Issue 6, pp. 7708 - 7717
Data from 423 human epidermal growth factor receptor 2‐negative (HER2−), hormone receptor‐positive (HR+) advanced breast cancer (aBC) patients treated with... 
advanced breast cancer, hormonal therapy | real‐world setting | endocrine resistance | palbociclib | real-world setting | 1ST-LINE TREATMENT | MULTICENTER | PLACEBO | PHYSIOLOGY | EFFICACY | SAFETY | COMBINATION | CELL BIOLOGY | WOMEN | FULVESTRANT | LETROZOLE | ABEMACICLIB | Work experience | Breast cancer | Therapy | Toxicity | Endocrine therapy | Patients | Survival | ErbB-2 protein | Metastases | Confidence intervals | Epidermal growth factor | Growth factors | Neutropenia | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
by Omarini, Claudia and Filieri, Maria Elisabetta and Bettelli, Stefania and Manfredini, Samantha and Kaleci, Shaniko and Caprera, Cecilia and Nasso, Cecilia and Barbolini, Monica and Guaitoli, Giorgia and Moscetti, Luca and Maiorana, Antonino and Conte, Pier Franco and Cascinu, Stefano and Piacentini, Federico
BioMed Research International, ISSN 2314-6133, 2018, Volume 2018, pp. 3756981 - 8
Background. Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | PIK3CA MUTATIONS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DNA | GROWTH | PTEN | INHIBITORS | PI3K/AKT/MTOR PATHWAY | ESTROGEN-RECEPTOR | Prospective Studies | Sirolimus | Humans | Middle Aged | Neoplasm Recurrence, Local | Phosphatidylinositol 3-Kinases - metabolism | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | DNA Mutational Analysis | Everolimus - therapeutic use | Female | Aged | Androstadienes - therapeutic use | Retrospective Studies | Genes, Neoplasm - genetics | TOR protein | Deregulation | Genes | Oncology | AKT protein | Metastasis | Kinases | Cancer therapies | Subgroups | Metastases | Genetic analysis | Lesions | Deoxyribonucleic acid--DNA | Medical research | Breast cancer | Patients | 1-Phosphatidylinositol 3-kinase | Studies | Correlation analysis | Point mutation | Biomarkers | Breast | Mutation | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Three missense mutations found in the KEL gene lead to Kmod or K0 red blood cell phenotypes
by